Creative Planning Purchases 141 Shares of Medpace Holdings, Inc. $MEDP

Creative Planning grew its stake in shares of Medpace Holdings, Inc. (NASDAQ:MEDP) by 2.6% in the second quarter, according to its most recent disclosure with the SEC. The fund owned 5,479 shares of the company’s stock after buying an additional 141 shares during the period. Creative Planning’s holdings in Medpace were worth $1,720,000 as of its most recent filing with the SEC.

A number of other institutional investors have also added to or reduced their stakes in the company. Vulcan Value Partners LLC lifted its stake in Medpace by 221.6% during the first quarter. Vulcan Value Partners LLC now owns 325,916 shares of the company’s stock worth $99,159,000 after purchasing an additional 224,578 shares during the period. Mawer Investment Management Ltd. raised its holdings in shares of Medpace by 17.4% in the 2nd quarter. Mawer Investment Management Ltd. now owns 817,432 shares of the company’s stock worth $256,559,000 after buying an additional 121,213 shares in the last quarter. Jacobs Levy Equity Management Inc. boosted its stake in Medpace by 675.8% in the 1st quarter. Jacobs Levy Equity Management Inc. now owns 121,464 shares of the company’s stock valued at $37,009,000 after buying an additional 105,807 shares in the last quarter. Invesco Ltd. grew its position in Medpace by 9.4% in the first quarter. Invesco Ltd. now owns 1,186,768 shares of the company’s stock valued at $361,596,000 after acquiring an additional 102,015 shares during the period. Finally, Northern Trust Corp raised its stake in Medpace by 36.0% during the first quarter. Northern Trust Corp now owns 337,489 shares of the company’s stock worth $102,830,000 after acquiring an additional 89,347 shares in the last quarter. 77.98% of the stock is owned by institutional investors and hedge funds.

Medpace Stock Down 0.9%

Medpace stock opened at $606.60 on Thursday. The company has a 50 day moving average of $556.49 and a 200-day moving average of $440.30. Medpace Holdings, Inc. has a twelve month low of $250.05 and a twelve month high of $626.26. The stock has a market capitalization of $17.09 billion, a PE ratio of 42.42, a price-to-earnings-growth ratio of 2.67 and a beta of 1.42.

Medpace (NASDAQ:MEDP) last announced its earnings results on Wednesday, October 22nd. The company reported $3.86 earnings per share for the quarter, topping analysts’ consensus estimates of $3.50 by $0.36. The firm had revenue of $659.90 million during the quarter, compared to analyst estimates of $640.49 million. Medpace had a net margin of 18.36% and a return on equity of 91.88%. The company’s revenue for the quarter was up 23.7% compared to the same quarter last year. During the same period in the prior year, the business earned $3.01 EPS. Medpace has set its FY 2025 guidance at 14.600-14.860 EPS. Equities analysts anticipate that Medpace Holdings, Inc. will post 12.29 EPS for the current fiscal year.

Insider Transactions at Medpace

In other Medpace news, VP Susan E. Burwig sold 20,000 shares of the business’s stock in a transaction that occurred on Monday, November 24th. The stock was sold at an average price of $609.15, for a total value of $12,183,000.00. Following the sale, the vice president owned 27,500 shares in the company, valued at approximately $16,751,625. The trade was a 42.11% decrease in their position. The transaction was disclosed in a legal filing with the SEC, which is accessible through this link. Also, President Jesse J. Geiger sold 21,503 shares of the company’s stock in a transaction that occurred on Wednesday, November 5th. The stock was sold at an average price of $595.66, for a total value of $12,808,476.98. Following the transaction, the president directly owned 15,000 shares of the company’s stock, valued at approximately $8,934,900. This trade represents a 58.91% decrease in their position. The SEC filing for this sale provides additional information. Insiders sold 346,963 shares of company stock valued at $203,105,238 over the last three months. 20.30% of the stock is currently owned by corporate insiders.

Analysts Set New Price Targets

A number of equities analysts have commented on MEDP shares. Truist Financial set a $555.00 price target on shares of Medpace in a research report on Monday, October 27th. Robert W. Baird set a $613.00 price objective on Medpace in a research note on Friday, October 24th. Zacks Research upgraded Medpace from a “hold” rating to a “strong-buy” rating in a research note on Monday, October 27th. BMO Capital Markets initiated coverage on shares of Medpace in a research report on Thursday, November 13th. They set a “market perform” rating and a $600.00 price target on the stock. Finally, Weiss Ratings reaffirmed a “buy (b)” rating on shares of Medpace in a research note on Friday, October 31st. One investment analyst has rated the stock with a Strong Buy rating, two have issued a Buy rating, ten have assigned a Hold rating and four have assigned a Sell rating to the company’s stock. According to data from MarketBeat, Medpace has an average rating of “Hold” and an average target price of $487.18.

Medpace Company Profile

Medpace Holdings, Inc engages in the provision of outsourced clinical development services to the biotechnology, pharmaceutical and medical device industries. Its services include medical department, clinical trial management, data-driven feasibility, study-start-up, clinical monitoring, regulatory affairs, patient recruitment and retention, medical writing, biometrics and data sciences, pharmacovigilance, core laboratory, laboratories, clinics, and quality assurance.